CompletedPhase 2NCT05387733
A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas
Studying Adiposis dolorosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Principal Investigator
- Anne SheuCaliway Biopharmaceuticals Co., Ltd.
- Intervention
- 10 mg CBL-514 per injection(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2022 – 2023
Study locations (1)
- Karen L. Herbst, MD, PC, Tucson, Arizona, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05387733 on ClinicalTrials.govOther trials for Adiposis dolorosa
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06303570A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease LipomasCaliway Biopharmaceuticals Co., Ltd.
- ENROLLING BY INVITATIONNCT00833599Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic DisordersThe University of Texas Health Science Center, Houston